
Opinion|Videos|November 4, 2024
Community Oncologist Perspective: Protocol Development for Bispecific Administration and AE Management
Dr Graff discusses how they developed protocols for administering bispecific antibodies and monitoring and managing associated adverse events.
Advertisement
Video content above is prompted by the following:
How did you develop your administration and adverse event monitoring and management protocols?
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
4
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
5






































